Pharmaceutical composition containing pyridylaminoacetic acid compound
US-2016317664-A1 · Nov 3, 2016 · US
Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
US11197849B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11197849-B2 |
| Application number | US-202016887108-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 29, 2020 |
| Priority date | Jan 10, 2014 |
| Publication date | Dec 14, 2021 |
| Grant date | Dec 14, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A liquid pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.001 to 0.003% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof; and water. 2. A liquid pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.002% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof; and water. 3. The liquid pharmaceutical preparation according to claim 1 , in which the preparation is for treatment of glaucoma. 4. The liquid pharmaceutical preparation according to claim 1 , in which the preparation is for treatment of ocular hypertension. 5. The liquid pharmaceutical preparation according to claim 1 , in which the preparation does not include other therapeutic agents for glaucoma. 6. The liquid pharmaceutical preparation according to claim 1 , in which the preparation is not used in combination with other therapeutic agents for glaucoma. 7. An eye drop comprising the liquid pharmaceutical preparation of claim 1 . 8. A method for treatment or prevention of glaucoma or ocular hypertension, comprising administrating the liquid pharmaceutical preparation of claim 1 to a patient who needs the treatment or prevention of glaucoma or ocular hypertension. 9. A method for treatment of glaucoma, comprising administrating the liquid pharmaceutical preparation of claim 3 to a patient who needs the treatment of glaucoma. 10. A method for treatment of ocular hypertension, comprising administrating the liquid pharmaceutical preparation of claim 4 to a patient who needs the treatment of ocular hypertension. 11. The method of claim 8 , in which the liquid preparation does not include other therapeutic agents for glaucoma. 12. The method of claim 8 , the liquid preparation is not used in combination with other therapeutic agents for glaucoma. 13. The method of claim 8 , in which the administrating is instillation. 14. The method of claim 13 , in which the instillation is provided once or twice a day. 15. The method of claim 8 , in which a dose of one or two drops is instilled. 16. The method of claim 8 , in which a dose of one drop is instilled once a day. 17. The method of claim 8 , wherein the patient is a human.
Assignees
Inventors
Classifications
- A61K31/444Primary
containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone · CPC title
Ophthalmic agents · CPC title
Eye, e.g. artificial tears · CPC title
Antiglaucoma agents or miotics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11197849B2 cover?
- Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
- Who is the assignee on this patent?
- Santen Pharmaceutical Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/444. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).